All Categories
Anti-CD8 VHH

Anti-CD8 VHH

Home >  Modality  >  Proteins  >  Nano-antibody  >  Anti-CD8 VHH

Modality

Anti-CD8 VHH

CD8 is highly expressed on tumor-infiltrating CD8+ T cells and CD8+ tumors and is considered an important marker of T lymphocytes. Anti-CD8 single-domain antibodies (sdAb), also called Heavy-Chain Variable (VHH) or nano-antibodies, are discovered for CD8+ positive tumor testing and treatment.

The 89 Zr-labeled PEGylated anti-CD8 sdAb (or called 89Zr-PEGylated-VHH-X118) was generated based on sortase-mediated site-specific conjugation to predict the reaction of tumors to anti-CTLA-4 treatment. It is demonstrated that the anti-CTLA-4 therapy responded well to tumors with homogenous absorption of 89Zr-PEGylated-VHH-X118 (tumors with homogenous distribution of CD8+ lymphocytes) and vice versa.

The other anti-CD8 nanobody immunoPET probe (68Ga-NOTA-SNA006a) had high yield and radiochemical purity. 68Ga-NOTA-SNA006a has a longer retention time, lower background, and higher tumor/blood ratio than that of other candidates.

A Phase I study (NCT05126927) of 68Ga-NOTA-CD8 targeting Nb (SNA006) is currently underway. In this study, PET imaging of 68 Ga-NOTA-SNA006 showed immediate quantification of CD8 expression with an ideal safety profile and is expected to play an important role in the dynamic monitoring of CD8+ T cells and immune reactions for individualized cancer immunotherapy.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for VHH/ sdAb
Anti-CD8 VHH In Development

Anti-CD8 VHH

Expression System

Stage

Clinical Trials

68Ga-NOTA-SNA006a

Mammalian cells

Phase 1

NCT05126927

89Zr-PEGylated-VHH-X118

Escherichia coli (E. coli)

Pre-clinical

Not applicable

Get a Free Quote

Get in touch